MedTrace Logo

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

NCT01959451 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2600

Last updated 2019-03-01

No results posted yet for this study

Summary

This study investigates whether a platelet function testing guided approach with a short-term (1 week) prasugrel treatment and a switch over to clopidogrel treatment in adequate responders to clopidogrel is non-inferior regarding the combined incidence of bleeding and thrombotic complications to a 12 month standard treatment with prasugrel in acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI).

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Prasugrel

see Arm description

DRUG

Clopidogrel

see arm description

Sponsors & Collaborators

  • LMU Klinikum

    lead OTHER

Principal Investigators

  • Dirk Sibbing, MD · Munich University Hospital

  • Julinda Mehilli, MD · Munich University Hospital

  • Steffen Massberg, MD · Munich University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-05-31
Completion
2017-06-30

Countries

  • Austria
  • Germany
  • Hungary
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959451 on ClinicalTrials.gov